VCEL
Vericel Corp OrdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.77B
P/E Ratio
80.77
EPS
$0.43
Beta
1.16
52W High
$45.97
52W Low
$28.95
50-Day MA
$33.84
200-Day MA
$35.42
Dividend Yield
—
Profit Margin
7.35%
Forward P/E
72.99
PEG Ratio
0.00
About Vericel Corp Ord
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cell therapies for the sports medicine and severe burn care markets in the United States. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $292.09M |
| Gross Profit (TTM) | $218.59M |
| EBITDA | $27.90M |
| Operating Margin | -11.80% |
| Return on Equity | 6.59% |
| Return on Assets | 2.17% |
| Revenue/Share (TTM) | $5.78 |
| Book Value | $6.98 |
| Price-to-Book | 4.98 |
| Price-to-Sales (TTM) | 6.07 |
| EV/Revenue | 5.9 |
| EV/EBITDA | 49.11 |
| Quarterly Earnings Growth (YoY) | 18.90% |
| Quarterly Revenue Growth (YoY) | 30.10% |
| Shares Outstanding | $51.07M |
| Float | $50.43M |
| % Insiders | 1.20% |
| % Institutions | 111.16% |
Historical Volatility
HV 10-Day
34.13%
HV 20-Day
49.00%
HV 30-Day
50.79%
HV 60-Day
47.50%
HV Rank
70.6%
Volatility is currently contracting
Analyst Ratings
Consensus ($55.43 target)
7
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026